Literature DB >> 1446593

Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides.

P S LaPolt1, K Nishimori, F A Fares, E Perlas, I Boime, A J Hsueh.   

Abstract

The induction of granulosa cell differentiation and follicle maturation is dependent upon the stimulatory actions of FSH. Our recent studies used recombinant DNA technology to fuse the carboxyl-terminal peptide (CTP) of hCG beta-subunit to the carboxyl-terminus of the FSH beta-subunit. The resulting FSH analog has identical in vitro receptor-binding and biological activities as wild-type FSH (WT-FSH), but an increased circulating half-life. The present studies examined further the ability of FSH with one (FSH-CTP1) or two (FSH-CTP2) appended CTPs to promote granulosa cell differentiation and follicle ovulatory potential. WT-FSH, FSH-CTP1, and FSH-CTP2 were produced from Chinese hamster ovary cells transfected with the common alpha-subunit and respective beta-subunit. Hormone concentrations were quantitated by RIA, and relative levels confirmed by radioligand receptor assay. Both FSH-CTP1 and FSH-CTP2 retained full FSH receptor-binding activity, but did not bind LH receptors. To compare in vivo bioactivity, immature estrogen-primed female rats received ip injections of FSH or the agonists at 0 and 24 h. At 48 h, substantial stimulation (up to 2.5-fold) of ovarian weight was induced by 1.0 and 3.0 IU/day FSH-CTP1 or FSH-CTP2, whereas a higher dose (10 IU/day) of WT-FSH was required for an 1.8-fold stimulation. Although the in vivo potencies of FSH-CTP1 and FSH-CTP2 were similar, FSH-CTPs were about 10-fold more potent than WT-FSH in inducing granulosa cell aromatase activity and LH receptors. We further reduced the frequency of hormone administration. Increasing doses (1-10 IU) of a single ip injection of FSH-CTP1 resulted in dose-dependent increases in granulosa cell aromatase activity and LH receptor content 48 h later. Although a single injection (10 IU) of WT-FSH had no effect, the same total dose of WT-FSH administered as four 2.5-IU injections 12 h apart was effective. To test the ovulatory potential of ovarian follicles, rats received a single injection of FSH-CTP1, followed 52 h later by 5 IU hCG to induce ovulation. Although hCG did not induce ovulation in females receiving a single dose (10 IU) of WT-FSH, 20 +/- 2 and 43 +/- 5 ovulated ova/rat were found in animals primed with 3 and 10 IU FSH-CTP1, respectively. Because twice daily injections of WT-FSH (2.5 IU/injection) also increased the ovulatory potential of the ovary, the enhanced effectiveness of FSH-CTP1 appears to be related to its increased circulating half-life.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446593     DOI: 10.1210/endo.131.6.1446593

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.

Authors:  Alberto Revelli; Giulia Pittatore; Simona Casano; Stefano Canosa; Francesca Evangelista; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2015-01-15       Impact factor: 3.412

2.  Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma.

Authors:  M M Elliott; A Kardana; J W Lustbader; L A Cole
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

Review 3.  Regulation of antral follicular growth by an interplay between gonadotropins and their receptors.

Authors:  Livio Casarini; Elia Paradiso; Clara Lazzaretti; Sara D'Alessandro; Neena Roy; Elisa Mascolo; Kornelia Zaręba; Alejandra García-Gasca; Manuela Simoni
Journal:  J Assist Reprod Genet       Date:  2022-03-15       Impact factor: 3.357

4.  A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.

Authors:  Alberto Revelli; Gianluca Gennarelli; Marta Sestero; Stefano Canosa; Andrea Carosso; Francesca Salvagno; Giulia Pittatore; Claudia Filippini; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2020-03-18       Impact factor: 3.412

5.  Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female mice.

Authors:  Rhonda K Trousdale; Bo Yu; Susan V Pollak; Nabil Husami; Andrea Vidali; Joyce W Lustbader
Journal:  Fertil Steril       Date:  2008-02-04       Impact factor: 7.329

6.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.

Authors:  Xiaotian Zhong; Jill F Wright
Journal:  Int J Cell Biol       Date:  2013-04-18

7.  Designing a Long Acting Erythropoietin by Fusing Three Carboxyl-Terminal Peptides of Human Chorionic Gonadotropin β Subunit to the N-Terminal and C-Terminal Coding Sequence.

Authors:  Fuad Fares; Avri Havron; Eyal Fima
Journal:  Int J Cell Biol       Date:  2011-08-21

8.  The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.

Authors:  Ayse Seyhan; Baris Ata
Journal:  Int J Womens Health       Date:  2011-08-08

9.  Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.

Authors:  Robert J Norman; Fernando Zegers-Hochschild; Bruno S Salle; Jolanda Elbers; Esther Heijnen; Maya Marintcheva-Petrova; Bernadette Mannaerts
Journal:  Hum Reprod       Date:  2011-05-27       Impact factor: 6.918

10.  A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.

Authors:  P Devroey; R Boostanfar; N P Koper; B M J L Mannaerts; P C Ijzerman-Boon; B C J M Fauser
Journal:  Hum Reprod       Date:  2009-08-14       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.